Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Medifast, Inc.NYSE: MED
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $1.1M (cash outflow) fell 28.0% year over year, behind the -27.3% change in trailing-twelve-month capital expenditures. Sequentially, it fell 18.9% from the prior quarter. Over 3 fiscal years it compounded at -30.4% a year.
Context
- Capital expenditures amounted to 1.5% of revenue in FY2025, up 0.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -28.0% toward the trailing-twelve-month pace of -27.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (5.61M) USD
- Year-over-year change
- +24.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.61M) | +24.7% |
| FY2024 | 2024-12-31 | (7.45M) | -15.0% |
| FY2023 | 2023-12-31 | (6.48M) | +61.1% |
| FY2022 | 2022-12-31 | (16.68M) | +51.2% |
| FY2021 | 2021-12-31 | (34.21M) | — |
Capital Expenditures vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.3% is the 9th highest of 10, against a peer median of +13.6%.
- Capital expenditures amounts to 1.5% of revenue for MED, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | $52.66M USD | +117.3% | +25.3% | 7.6% | |
| LTM Mar 2026 | $16.22M USD | +13.6% | -5.1% | 2.7% | |
| LTM May 2026 | $11.79M USD | +18.7% | -27.6% | 1.2% | |
| LTM Mar 2026 | $5.54M USD | -8.0% | -14.5% | 2.2% | |
| LTM Mar 2026 | $5.19M USD | -27.3% | -30.4% | 1.5% | |
| LTM Feb 2026 | $4.52M USD | +12.9% | -40.3% | 1.4% | |
| LTM Jan 2026 | $3.53M USD | +34.1% | +4.3% | 1.2% | |
| FY2025 | HK$1.38M HKD | -88.5% | -65.2% | 0.3% | |
| LTM Mar 2026 | $1.15M USD | -12.9% | -27.0% | 1.3% | |
AIIORobo.ai Inc. | FY2025 | $0 USD | +100.0% | — | 0.0% |
| Peer median (excluding MED) | — | +13.6% | -20.8% | 1.3% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 17.4M | 14.24M |
| Deferred Income Tax | (3.72M) | (924K) | 1.21M | (7.4M) | 11.46M |
| Stock-Based Compensation | 9.9M | 11.05M | 8.19M | 7.36M | 7.64M |
| Change in Working Capital | (87.65M) | 21.65M | 20.28M | (9.75M) | (9.81M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | (126.65M) | 61.19M | 64.27M | 12.17M | 22.19M |
| Accounts Payables | 54.38M | (37.59M) | (35.71M) | (34.99M) | (23.91M) |
| Other Working Capital | 39.01M | (1.94M) | (8.28M) | 13.08M | (8.09M) |
| Other Non-Cash Items | 5.16M | 8.24M | 5.46M | 14.77M | 2M |
| Operating Cash Flow | 94.55M | 194.57M | 147.66M | 24.48M | 6.86M |
| Capital Expenditures | (34.21M) | (16.68M) | (6.48M) | (7.45M) | (5.61M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (54.56M) | (46.6M) | (84.41M) |
| Sales of Investments | 5.15M | 5.27M | 0 | 27.43M | 78.78M |
| Other Investing Activities | 0 | 0 | 0 | 95K | 3.31M |
| Investing Cash Flow | (29.06M) | (11.41M) | (61.05M) | (26.52M) | (7.93M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (62.09M) | (127.96M) | (6.96M) | (836K) | (369K) |
| Dividends Paid | (63.86M) | (71.62M) | (73.02M) | (715K) | (195K) |
| Other Financing Activities | 811K | 0 | 188K | 36K | 0 |
| Financing Cash Flow | (125.13M) | (199.58M) | (79.79M) | (1.52M) | (564K) |
| Effect of Forex Changes | 112K | (67K) | (72K) | 47K | 4K |
| Net Change in Cash | (59.54M) | (16.49M) | 6.75M | (3.51M) | (1.63M) |
| Free Cash Flow | 60.34M | 177.89M | 141.17M | 17.02M | 1.25M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.